Back to search results

Transcutaneous Auricular Neurostimulation (tAN) for PMDD and Perimenopause

This study is testing a device called transcutaneous auricular neurostimulation (tAN), specifically using the Sparrow Link device, for women experiencing Premenstrual Dysphoric Disorder (PMDD) or perimenopause symptoms. The tAN device works by stimulating nerves around the ear. Researchers want to see if using this device can improve your symptoms. You may be able to join if you are a woman between 18 and 55 years old, have regular menstrual cycles, and identify as having PMS or PMDD. The study will measure symptom improvement using daily and monthly surveys. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 20 participants. It is not specified if it is randomized or blinded.
What's involved
If you have PMS/PMDD, you would participate for about four months, including a baseline, two treatment cycles, and a follow-up cycle. If you have perimenopause, you would participate for about three months, including a baseline, one treatment month, and a follow-up month. You will complete daily and monthly surveys.
Compensation
Not stated in the trial record.
Follow-up
For PMDD/PMS, participants are followed for one menstrual cycle after treatment. For perimenopause, participants are followed for one month after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07688720

Transcutaneous Auricular Neurostimulation (tAN) for Premenstrual Dysphoric Disorder (PMDD) and Perimenopause

Recruiting
NAAges 18–55InterventionalTreatment
Texas Christian University
~20 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:transcutaneous auricular neurostimulation (tAN)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Daily Record of Severity of Problems (DRSP)
Measured over Assessed daily from study initiation until the end of the study, an average of four months (4 cycles). Menstrual cycle length varies but is generally 21-35 days.
+1 more outcome measured

Conditions

Perimenopause
PMDD

Explore related trials

PerimenopausalPremenstrual Dysphoric DisorderPremenstrual syndrome

NCT07688720

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Texas Christian University

    Fort Worth, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Sarah E Hill, PhD · PRINCIPAL_INVESTIGATOR · Texas Christian University

Who to contact

Sarah E Hill, PhD
[email protected]
817-257-6424
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Assigned female at birth
Age 18 to 45
Naturally cycling
Regularly occurring menstrual cycle
Must identify as having PMS or PMDD
Reliable ability to complete online study surveys
Assigned female at birth.
Age 40 to 55
Must have newly variable menstrual cycles or report identifying as perimenopausal
Reliable ability to complete online study surveys

Exclusion

Using hormonal birth control
Pregnant or lactating/breastfeeding
History of seizures
Implanted devices
Current or previous diagnosis of any heart conditions
Abnormal ear anatomy
Non-removable piercings on the ear
Recent ear infection
Taking SSRIs
Taking steroids
Taking hormone therapy
If the participant anticipates starting or stopping prescription medications during the study period
Participant has a history of neurologic diseases (i.e. stroke, brain tumor, cerebrovascular, etc.)
Participant has a history traumatic brain injury within the past 12 months
Must not have any other mental illness or mood disorder
Using hormonal birth control
Pregnant or lactating/breastfeeding
History of seizures
Implanted devices
Current or previous diagnosis of any heart conditions
Abnormal ear anatomy
Non-removable piercings on the ear
Recent ear infection
Taking SSRIs
Taking steroids
Taking hormone therapy
If the participant anticipates starting or stopping prescription medications during the study period.
Participant has a history of neurologic diseases (i.e. stroke, brain tumor, cerebrovascular, etc.)
Participant has a history traumatic brain injury within the past 12 months
have a hysterectomy

What this trial measures

  • Daily Record of Severity of Problems (DRSP)Assessed daily from study initiation until the end of the study, an average of four months (4 cycles). Menstrual cycle length varies but is generally 21-35 days.

    The DRSP assesses psychological and physical premenstrual symptoms. This is the primary outcome in the PMS/PMDD study.

  • Green Climacteric ScaleParticipants will complete this measure monthly from study initiation until the end of the study, about three months.

    The Green Climacteric Scale assesses the degree to which respondents are bothered by a range of different menopausal symptoms. This is the primary outcome in the Perimenopause Study.